Results 291 to 300 of about 112,794 (342)
Some of the next articles are maybe not open access.

Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation

European Journal of Pharmacology, 1998
The anti-inflammatory activity of drugs more selective for cyclooxgenase isoform inhibition (cyclooxygenase 1, cyclooxygenase 2), were compared in rat carrageenin-induced pleurisy. Suppression of inflammation by cyclooxygenase 2-selective inhibitors, NS-398 (N-[-2-cyclohexyloxy]-4-nitrophenyl methanesulphonamide) and nimesulide (4-nitro-2-phenoxy ...
D W, Gilroy   +2 more
openaire   +4 more sources

Cyclooxygenase-2 inhibitors

Current Opinion in Internal Medicine, 2006
The purpose of this review is to summarize new information regarding the use of selective inhibitors of the cyclooxygenase-2 enzyme, emphasizing recent developments regarding cardiovascular risk.Selective cyclooxygenase-2 inhibitors are as effective as nonselective nonsteroidal antiinflammatory drugs in relieving pain and inflammation but are ...
Christopher J, Hawkey, Paul J, Fortun
  +5 more sources

Cyclooxygenase‐independent actions of cyclooxygenase inhibitors

The FASEB Journal, 2001
Several studies have demonstrated unequivocally that certain nonsteroidal anti‐inflammatory drugs (NSAIDs) such as sodium salicylate, sulindac, ibuprofen, and flurbiprofen cause anti‐inflammatory and antiproliferative effects independent of cyclooxy‐genase activity and prostaglandin synthesis inhibition.
I, Tegeder   +2 more
openaire   +2 more sources

Cyclooxygenase Inhibitors

2013
Cyclooxygenase (COX) inhibitors are widely used to relieve musculoskeletal pain. COX inhibitors are a group of heterogenous substances including non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol (acetaminophen). Moreover, various selective cyclooxygenase-2 (COX-2) inhibitors with improved gastrointestinal tolerability as compared with ...
Burkhard Hinz, Kay Brune
openaire   +2 more sources

Cyclooxygenase-2 inhibitors

2001
Publisher Summary This chapter deals with aspects of the discovery and development of Cyclooxygenase-2 (Cox-2) inhibitors, which, in the case of rofecoxib, resulted from efforts that were initiated in July of 1992 and culminated in the launch of the drug in the United States in June of 1999. Nonsteroidal antiinflammatory drugs (NSAIDs) have long been
A S, Nies, M J, Gresser
openaire   +2 more sources

Pharmacodynamic of cyclooxygenase inhibitors in humans

Prostaglandins & Other Lipid Mediators, 2007
We provide comprehensive knowledge on the differential regulation of expression and catalysis of cyclooxygenase (COX)-1 and COX-2 in health and disease which represents an essential requirement to read out the clinical consequences of selective and nonselective inhibition of COX-isozymes in humans.
CAPONE ML   +5 more
openaire   +2 more sources

The classification of cyclooxygenase inhibitors.

The Journal of rheumatology, 1998
Item does not contain ...
Lipsky, P.E.   +5 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy